Core Insights - ClearBridge Investments reported that mid-cap stocks experienced growth in Q3 2025, driven by a favorable monetary policy environment and stabilizing earnings [1] - The Federal Reserve's rate cuts positively impacted small and mid-cap stocks, with value stocks outperforming growth stocks [1] - The ClearBridge Mid Cap Strategy outperformed the Russell Midcap Index, primarily due to stock selection in the consumer staples and healthcare sectors [1] Company Highlights - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was highlighted for its strong performance, with a one-month return of -3.73% but a 52-week gain of 75.54% [2] - As of November 12, 2025, Alnylam's stock closed at $452.74, with a market capitalization of $59.81 billion [2] - The company reported a 103% year-over-year growth in product revenue for Q3 2025, reaching $851 million [4] Sector Performance - The healthcare sector, particularly biotechnology, was a key driver of outperformance for the ClearBridge Mid Cap Strategy [3] - Alnylam's growth was attributed to the increasing uptake of its treatment for transthyretin cardiac amyloidosis (ATTR-CM) and an upward revision of its full-year revenue guidance [3]